Clevudine myopathy in patients with chronic hepatitis B

Byung Kook Kim; Jeeyoung Oh; So Young Kwon; Won Hyeok Choe; Soon Young Ko; Kyoung Hoon Rhee; Tae Ho Seo; So Dug Lim; Chang Hong Lee

doi:10.1016/j.jhep.2009.04.019

Clevudine myopathy in patients with chronic hepatitis B

J Hepatol. 2009 Oct;51(4):829-34. doi: 10.1016/j.jhep.2009.04.019. Epub 2009 May 28.

Authors

Byung Kook Kim¹, Jeeyoung Oh, So Young Kwon, Won Hyeok Choe, Soon Young Ko, Kyoung Hoon Rhee, Tae Ho Seo, So Dug Lim, Chang Hong Lee

Affiliation

¹ Department of Internal Medicine, Konkuk University School of Medicine, 4-12 Hwayang-dong, Gwangjin-gu, Seoul 143-729, Republic of Korea.

PMID: 19615776
DOI: 10.1016/j.jhep.2009.04.019

Abstract

Clevudine (L-FMAU) is a thymidine l-nucleoside analogue that was recently introduced for the treatment of chronic hepatitis B virus infection. Previous studies showed that clevudine has potent and sustained antiviral activity without causing viral resistance. No severe adverse event occurred during clinical trials. We describe two cases of drug-induced myopathy during long-term treatment of chronic hepatitis B with clevudine.

Publication types

Case Reports

MeSH terms

Adult
Antiviral Agents / adverse effects*
Arabinofuranosyluracil / adverse effects
Arabinofuranosyluracil / analogs & derivatives*
Creatine Kinase / blood
DNA, Viral / blood
Electromyography
Female
Hepatitis B virus / isolation & purification
Hepatitis B, Chronic / drug therapy*
Hepatitis B, Chronic / virology
Humans
Middle Aged
Muscular Diseases / chemically induced*
Muscular Diseases / pathology
Muscular Diseases / physiopathology

Substances

Antiviral Agents
DNA, Viral
Arabinofuranosyluracil
Creatine Kinase
clevudine